Considering that we have provided pharmacologic evidence for uncharacterized CTED mutants as well, we think even larger proportion of patients with GBM or lung cancer may benefit from EGFR targeted therapies than what is predicted. The gene discussed is EGFR; the disease is glioblastoma.